Naif Khalaf Alharbi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5291014/publications.pdf

Version: 2024-02-01

39 papers	1,063 citations	516561 16 h-index	434063 31 g-index
42 all docs	42 docs citations	42 times ranked	2132 citing authors

#	Article	IF	Citations
1	Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial. Lancet Microbe, The, 2022, 3, e11-e20.	3.4	25
2	Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial. Clinical Microbiology and Infection, 2022, 28, 602-608.	2.8	60
3	A combined model for COVID-19 pandemic control: The application of Haddon's matrix and community risk reduction tools combined. Journal of Infection and Public Health, 2022, 15, 261-269.	1.9	7
4	Outcomes of single dose COVID-19 vaccines: Eight month follow-up of a large cohort in Saudi Arabia. Journal of Infection and Public Health, 2022, 15, 573-577.	1.9	7
5	Seroprevalence of COVID-19 in Riyadh city during the early increase of COVID-19 infections in Saudi Arabia, June 2020. Saudi Journal of Biological Sciences, 2022, 29, 103282.	1.8	1
6	Seroprevalence of SARS-CoV-2 (COVID-19) among healthcare workers in Saudi Arabia: comparing case and control hospitals. Diagnostic Microbiology and Infectious Disease, 2021, 99, 115273.	0.8	61
7	COVID-19 vaccines: Global challenges and prospects forum recommendations. International Journal of Infectious Diseases, 2021, 105, 448-451.	1.5	7
8	Proteomics-based identification of cancer-associated proteins in chronic lymphocytic leukaemia. Electronic Journal of Biotechnology, 2021, 52, 1-12.	1.2	1
9	Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia. Journal of Infection and Public Health, 2021, 14, 832-838.	1.9	27
10	Seroprevalence of Viral Hepatitis B and C among Blood Donors in the Northern Region of Riyadh Province, Saudi Arabia. Healthcare (Switzerland), 2021, 9, 934.	1.0	5
11	Early Prediction of COVID-19 Ventilation Requirement and Mortality from Routinely Collected Baseline Chest Radiographs, Laboratory, and Clinical Data with Machine Learning. Journal of Multidisciplinary Healthcare, 2021, Volume 14, 2017-2033.	1.1	21
12	Transcriptomic Profiling of Dromedary Camels Immunised with a MERS Vaccine Candidate. Veterinary Sciences, 2021, 8, 156.	0.6	0
13	Seroprevalence of SARS-CoV-2 among high-risk healthcare workers in a MERS-CoV endemic area. Journal of Infection and Public Health, 2021, 14, 1268-1273.	1.9	7
14	Haematological and radiological-based prognostic markers of COVID-19. Journal of Infection and Public Health, 2021, 14, 1650-1657.	1.9	8
15	Immune Responses to MERS-CoV in Humans and Animals. Advances in Experimental Medicine and Biology, 2021, 1313, 85-97.	0.8	0
16	Viruses causing aseptic meningitis: A tertiary medical center experience with a multiplex PCR assay. Journal of the Neurological Sciences, 2021, 429, 118905.	0.3	0
17	Non-SARS Non-MERS Human Coronaviruses: Clinical Characteristics and Outcome. Pathogens, 2021, 10, 1549.	1.2	3
18	Transcriptomics-Based Characterization of the Toxicity of ZnO Nanoparticles Against Chronic Myeloid Leukemia Cells . International Journal of Nanomedicine, 2020, Volume 15, 7901-7921.	3.3	22

#	Article	IF	Citations
19	Interferon Beta-1b and Lopinavirâ€“Ritonavir for Middle East Respiratory Syndrome. New England Journal of Medicine, 2020, 383, 1645-1656.	13.9	61
20	Viruses Causing Aseptic Meningitis: A Tertiary Medical Center Experience With a Multiplex PCR Assay. Frontiers in Neurology, 2020, 11, 602267.	1.1	14
21	Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients. Viruses, 2020, 12, 1390.	1.5	42
22	High Rate of Circulating MERS-CoV in Dromedary Camels at Slaughterhouses in Riyadh, 2019. Viruses, 2020, 12, 1215.	1.5	13
23	Seroprevalence of MERS-CoV in healthy adults in western Saudi Arabia, 2011â€“2016. Journal of Infection and Public Health, 2020, 13, 697-703.	1.9	17
24	Generation of MERS-CoV Pseudotyped Viral Particles for the Evaluation of Neutralizing Antibodies in Mammalian Sera. Methods in Molecular Biology, 2020, 2099, 117-126.	0.4	16
25	Preparedness and response to COVID-19 in Saudi Arabia: Building on MERS experience. Journal of Infection and Public Health, 2020, 13, 834-838.	1.9	250
26	Challenge infection model for MERS-CoV based on naturally infected camels. Virology Journal, 2020, 17, 77.	1.4	8
27	Poxviral promoters for improving the immunogenicity of MVA delivered vaccines. Human Vaccines and Immunotherapeutics, 2019, 15, 203-209.	1.4	22
28	Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels. Scientific Reports, 2019, 9, 16292.	1.6	72
29	A Highly Immunogenic, Protective, and Safe Adenovirus-Based Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model. Journal of Infectious Diseases, 2019, 220, 1558-1567.	1.9	64
30	Antimicrobial resistance: A round table discussion on the â€œOne Healthâ€•concept from the Gulf Cooperation Council Countries. Part One: A focus on Leadership. Journal of Infection and Public Health, 2018, 11, 771-777.	1.9	13
31	Antimicrobial resistance: A round table discussion on the â€œOne Healthâ€•concept from the Gulf Cooperation Council Countries. Part Two: A focus on Human Health. Journal of Infection and Public Health, 2018, 11, 778-783.	1.9	7
32	ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine, 2017, 35, 3780-3788.	1.7	133
33	Vaccines against Middle East respiratory syndrome coronavirus for humans and camels. Reviews in Medical Virology, 2017, 27, e1917.	3.9	19
34	Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter. Vaccine, 2016, 34, 49-55.	1.7	13
35	Investigation of IRES Insertion into the Genome of Recombinant MVA as a Translation Enhancer in the Context of Transcript Decapping. PLoS ONE, 2015, 10, e0127978.	1.1	1
36	Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity. PLoS ONE, 2015, 10, e0128626.	1.1	12

#	Article	IF	Citations
37	Expression and Cellular Immunogenicity of a Transgenic Antigen Driven by Endogenous Poxviral Early Promoters at Their Authentic Loci in MVA. PLoS ONE, 2012, 7, e40167.	1.1	22
38	Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia. SSRN Electronic Journal, 0, , .	0.4	0
39	Prevalence of MERS-CoV in Healthy Adults in Western Saudi Arabia, 2011-2016; a Retrospective, Cross-Sectional Seroepidemiological Study. SSRN Electronic Journal, 0, , .	0.4	1